Table 5.
Number of Significant Features for Each Study
| Drug Review Name | Total No. of Significant Features | Word Features | MeSH Features | PubType Features |
|---|---|---|---|---|
| ACEInhibitors | 210 | 165 | 40 | 5 |
| ADHD | 80 | 56 | 24 | 0 |
| Antihistamines | 29 | 19 | 9 | 1 |
| AtypicalAntipsychotics | 381 | 302 | 71 | 8 |
| BetaBlockers | 194 | 147 | 42 | 5 |
| CalciumChannelBlockers | 329 | 247 | 77 | 5 |
| Estrogens | 233 | 184 | 44 | 5 |
| NSAIDs | 242 | 186 | 51 | 5 |
| Opioids | 55 | 41 | 14 | 0 |
| OralHypoglycemics | 234 | 175 | 55 | 4 |
| ProtonPumpInhibitors | 206 | 146 | 54 | 6 |
| SkeletalMuscleRelaxants | 11 | 7 | 2 | 2 |
| Statins | 467 | 374 | 87 | 6 |
| Triptans | 121 | 96 | 22 | 3 |
| UrinaryIncontinence | 215 | 165 | 45 | 5 |
MeSH = medical subject headings; ACE = angiotensin-converting enzyme; ADHD = attention-deficit/hyperactivity disorder; NSAIDs = nonsteroidal anti-inflammatory drugs.